ArticleJACC. Case reports2026
Patency of Distal Aortic Occlusion Treated With DCBs in a 13-Year-Old Child With TA.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistal aortic occlusion in pediatric patients with Takayasu arteritis (TA) has been very challenging to treat, especially in choosing a definitive revascularization strategy. Stenting significantly increases patency; however, the diameter might be undersized when the patient reaches adulthood. CASE SUMMARY: We reported a case of a 13-year-old girl with distal aortic occlusion caused by TA, which was successfully treated with drug-coated balloons (DCBs) in which the patency can be maintained over 2 years. DISCUSSION: DCBs, mainly paclitaxel, help mitigate the risk of restenosis by inhibiting the proliferation of smooth muscle and intimal hyperplasia, which are both key factors of restenosis in inflammatory vascular conditions such as TA. TAKE-HOME MESSAGE: DCBs might be a promising alternative to treat pediatric patients with TA presenting with distal aortic occlusion as it could help maintain patency while still giving chances for the arteries to grow until the patient reaches adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.